Coronado, C. Cortés-Funes Castro, Hernán López Martín, Ana Paz-Ares Rodríguez, Luis
Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. [artículo] - Cancer chemotherapy and pharmacology, 2013 - 72(1):75-83.
Formato Vancouver:
Salazar R, Cortés-Funes H, Casado E, Pardo B, López-Martín A, Cuadra C et al. Phase I study of weekly kahalalide
F as prolonged infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul;72(1):75-83.
PMID: 23645288
Contiene 18 referencias
PURPOSE: Kahalalide F (KF) is a dehydroaminobutyric acid-containing peptide from marine origin with activity against several human malignant cell lines. This dose-escalating phase I clinical trial evaluated the maximum tolerated dose (MTD), and the recommended dose for further phase II studies (RD) of weekly KF given as a prolonged (3- to 24-h) intravenous (i.v.) infusion.
Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. [artículo] - Cancer chemotherapy and pharmacology, 2013 - 72(1):75-83.
Formato Vancouver:
Salazar R, Cortés-Funes H, Casado E, Pardo B, López-Martín A, Cuadra C et al. Phase I study of weekly kahalalide
F as prolonged infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul;72(1):75-83.
PMID: 23645288
Contiene 18 referencias
PURPOSE: Kahalalide F (KF) is a dehydroaminobutyric acid-containing peptide from marine origin with activity against several human malignant cell lines. This dose-escalating phase I clinical trial evaluated the maximum tolerated dose (MTD), and the recommended dose for further phase II studies (RD) of weekly KF given as a prolonged (3- to 24-h) intravenous (i.v.) infusion.
